Malignancy rates of stereotactic biopsies of two or more distinct sites of suspicious calcifications in women without known breast cancer

Research output: Contribution to journalArticle

Abstract

Objective: To determine the malignancy rate in women without a concurrent breast cancer diagnosis at presentation who underwent stereotactic biopsies of distinct sites of suspicious calcifications. Methods: This retrospective study included 280 women without a concurrent breast cancer diagnosis who underwent 587 stereotactic biopsies of two or more distinct sites of suspicious calcifications in one or both breasts at our institution from 2010 to 2015. Results: The overall malignancy rate was 27.9% (78/280, 95% CI, 22.7%–33.5%) at the patient level and 18.7% (110/587, 95% CI, 15.7%–22.1%) at the lesion level. Eighteen had invasive cancers (mean [range] diameter, 0.5 cm [0.1–1.7]; six grade I, ten grade II, two grade III), one of whom had multifocal and another bilateral malignancy. Sixty had ductal carcinoma in situ. Of the 171 with all calcifications of the same morphology, 139 (81.3%) had all calcifications in the same pathology category (benign, high-risk, or malignant). Conclusion: The malignancy rate is substantial in women who undergo stereotactic biopsies of two or more distinct calcification sites. Given the nearly 20% rate of dissimilar histopathology between calcification sites with similar morphology, if only one site is biopsied and results in a malignant pathology, biopsy of the additional calcifications is warranted. Even if the pathology result of the one site biopsy is benign, biopsy of additional sites may perhaps still be necessary.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalClinical Imaging
Volume58
DOIs
StatePublished - Nov 1 2019

Fingerprint

Breast Neoplasms
Biopsy
Neoplasms
Pathology
Carcinoma, Intraductal, Noninfiltrating
Breast
Retrospective Studies

Keywords

  • Breast calcifications
  • Breast cancer
  • Stereotactic biopsy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{1da5047f375d4c4b831884d049a35a41,
title = "Malignancy rates of stereotactic biopsies of two or more distinct sites of suspicious calcifications in women without known breast cancer",
abstract = "Objective: To determine the malignancy rate in women without a concurrent breast cancer diagnosis at presentation who underwent stereotactic biopsies of distinct sites of suspicious calcifications. Methods: This retrospective study included 280 women without a concurrent breast cancer diagnosis who underwent 587 stereotactic biopsies of two or more distinct sites of suspicious calcifications in one or both breasts at our institution from 2010 to 2015. Results: The overall malignancy rate was 27.9{\%} (78/280, 95{\%} CI, 22.7{\%}–33.5{\%}) at the patient level and 18.7{\%} (110/587, 95{\%} CI, 15.7{\%}–22.1{\%}) at the lesion level. Eighteen had invasive cancers (mean [range] diameter, 0.5 cm [0.1–1.7]; six grade I, ten grade II, two grade III), one of whom had multifocal and another bilateral malignancy. Sixty had ductal carcinoma in situ. Of the 171 with all calcifications of the same morphology, 139 (81.3{\%}) had all calcifications in the same pathology category (benign, high-risk, or malignant). Conclusion: The malignancy rate is substantial in women who undergo stereotactic biopsies of two or more distinct calcification sites. Given the nearly 20{\%} rate of dissimilar histopathology between calcification sites with similar morphology, if only one site is biopsied and results in a malignant pathology, biopsy of the additional calcifications is warranted. Even if the pathology result of the one site biopsy is benign, biopsy of additional sites may perhaps still be necessary.",
keywords = "Breast calcifications, Breast cancer, Stereotactic biopsy",
author = "{Chang Sen}, {Lauren Q} and Huang, {Monica L.} and Jessica Leung and Wei Wei and Adrada, {Beatriz Elena}",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.clinimag.2019.07.007",
language = "English (US)",
volume = "58",
pages = "156--160",
journal = "Clinical Imaging",
issn = "0899-7071",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Malignancy rates of stereotactic biopsies of two or more distinct sites of suspicious calcifications in women without known breast cancer

AU - Chang Sen, Lauren Q

AU - Huang, Monica L.

AU - Leung, Jessica

AU - Wei, Wei

AU - Adrada, Beatriz Elena

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Objective: To determine the malignancy rate in women without a concurrent breast cancer diagnosis at presentation who underwent stereotactic biopsies of distinct sites of suspicious calcifications. Methods: This retrospective study included 280 women without a concurrent breast cancer diagnosis who underwent 587 stereotactic biopsies of two or more distinct sites of suspicious calcifications in one or both breasts at our institution from 2010 to 2015. Results: The overall malignancy rate was 27.9% (78/280, 95% CI, 22.7%–33.5%) at the patient level and 18.7% (110/587, 95% CI, 15.7%–22.1%) at the lesion level. Eighteen had invasive cancers (mean [range] diameter, 0.5 cm [0.1–1.7]; six grade I, ten grade II, two grade III), one of whom had multifocal and another bilateral malignancy. Sixty had ductal carcinoma in situ. Of the 171 with all calcifications of the same morphology, 139 (81.3%) had all calcifications in the same pathology category (benign, high-risk, or malignant). Conclusion: The malignancy rate is substantial in women who undergo stereotactic biopsies of two or more distinct calcification sites. Given the nearly 20% rate of dissimilar histopathology between calcification sites with similar morphology, if only one site is biopsied and results in a malignant pathology, biopsy of the additional calcifications is warranted. Even if the pathology result of the one site biopsy is benign, biopsy of additional sites may perhaps still be necessary.

AB - Objective: To determine the malignancy rate in women without a concurrent breast cancer diagnosis at presentation who underwent stereotactic biopsies of distinct sites of suspicious calcifications. Methods: This retrospective study included 280 women without a concurrent breast cancer diagnosis who underwent 587 stereotactic biopsies of two or more distinct sites of suspicious calcifications in one or both breasts at our institution from 2010 to 2015. Results: The overall malignancy rate was 27.9% (78/280, 95% CI, 22.7%–33.5%) at the patient level and 18.7% (110/587, 95% CI, 15.7%–22.1%) at the lesion level. Eighteen had invasive cancers (mean [range] diameter, 0.5 cm [0.1–1.7]; six grade I, ten grade II, two grade III), one of whom had multifocal and another bilateral malignancy. Sixty had ductal carcinoma in situ. Of the 171 with all calcifications of the same morphology, 139 (81.3%) had all calcifications in the same pathology category (benign, high-risk, or malignant). Conclusion: The malignancy rate is substantial in women who undergo stereotactic biopsies of two or more distinct calcification sites. Given the nearly 20% rate of dissimilar histopathology between calcification sites with similar morphology, if only one site is biopsied and results in a malignant pathology, biopsy of the additional calcifications is warranted. Even if the pathology result of the one site biopsy is benign, biopsy of additional sites may perhaps still be necessary.

KW - Breast calcifications

KW - Breast cancer

KW - Stereotactic biopsy

UR - http://www.scopus.com/inward/record.url?scp=85069926515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069926515&partnerID=8YFLogxK

U2 - 10.1016/j.clinimag.2019.07.007

DO - 10.1016/j.clinimag.2019.07.007

M3 - Article

AN - SCOPUS:85069926515

VL - 58

SP - 156

EP - 160

JO - Clinical Imaging

JF - Clinical Imaging

SN - 0899-7071

ER -